Krystal Biotech (NASDAQ:KRYS) Hits New 12-Month High Following Better-Than-Expected Earnings

Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) hit a new 52-week high on Wednesday after the company announced better than expected quarterly earnings. The stock traded as high as $298.30 and last traded at $287.84, with a volume of 842516 shares. The stock had previously closed at $276.45.

The company reported $1.70 earnings per share for the quarter, beating analysts’ consensus estimates of $1.62 by $0.08. Krystal Biotech had a return on equity of 18.69% and a net margin of 52.64%.The business had revenue of $107.11 million during the quarter, compared to analysts’ expectations of $105.30 million.

Key Stories Impacting Krystal Biotech

Here are the key news stories impacting Krystal Biotech this week:

• Positive Sentiment: Q4 earnings beat consensus and management highlighted Vyjuvek sales growth and pipeline progress — Vyjuvek sales rose (~17% cited by coverage) and the company reported expanding U.S. reimbursements (660+), supporting revenue and margin outlooks. Read More.
• Positive Sentiment: Analysts are lifting targets and maintaining Buy views — Chardan raised its price target to $323 (Buy) and HC Wainwright keeps a Buy with a $310 target and quarterly EPS estimates, signaling continued analyst confidence. Read More. and Read More.
• Positive Sentiment: Pipeline expansion: KB707 and RMAT designation narrative gaining attention — coverage highlights KB707’s role in an oncology story and broader HSV‑1 platform opportunities, which supports longer‑term upside. Read More.
• Neutral Sentiment: Analysts and media are re‑rating the story after new data and target resets — several pieces reassess valuation and strategy after the one‑year rally; useful for investors reassessing risk/reward. Read More.
• Neutral Sentiment: Q4 earnings call transcript and coverage available for deeper read — transcript and analyst notes give more detail on international launches (Italy H2 2026) and margin targets (90–95%). Read More.
• Neutral Sentiment: Short‑interest data shows no meaningful days‑to‑cover signal in the most recent snapshot — not a driver of today’s move. (Report entry: short interest flagged as zero.)
• Negative Sentiment: Stock pulled back despite earnings beat — several outlets note intraday selling and a slip after the print, consistent with profit‑taking following the stock’s strong run and some mixed readthroughs on revenue/margins. Read More.
• Negative Sentiment: Market reaction may reflect short‑term rotation and valuation scrutiny after a one‑year rally to new highs — investors may be locking gains even as fundamental metrics remain supportive. Read More.

Analysts Set New Price Targets

Several analysts have recently commented on the stock. Chardan Capital increased their price target on shares of Krystal Biotech from $220.00 to $323.00 and gave the company a “buy” rating in a research report on Wednesday. Zacks Research cut Krystal Biotech from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 5th. Bank of America raised their price target on Krystal Biotech from $288.00 to $318.00 and gave the stock a “buy” rating in a research report on Thursday, January 22nd. Weiss Ratings raised Krystal Biotech from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday. Finally, Citigroup increased their price objective on Krystal Biotech from $336.00 to $371.00 and gave the company a “buy” rating in a research note on Wednesday. Nine investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, Krystal Biotech has a consensus rating of “Moderate Buy” and a consensus price target of $318.75.

Insider Buying and Selling

In other Krystal Biotech news, CAO Kathryn Romano sold 12,500 shares of Krystal Biotech stock in a transaction on Monday, February 9th. The shares were sold at an average price of $272.14, for a total value of $3,401,750.00. Following the transaction, the chief accounting officer owned 19,318 shares in the company, valued at $5,257,200.52. This trade represents a 39.29% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction on Thursday, December 4th. The shares were sold at an average price of $220.16, for a total value of $5,504,000.00. Following the completion of the transaction, the insider owned 1,413,711 shares in the company, valued at $311,242,613.76. The trade was a 1.74% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 13.70% of the company’s stock.

Institutional Trading of Krystal Biotech

Institutional investors have recently modified their holdings of the company. Hantz Financial Services Inc. raised its holdings in Krystal Biotech by 8,950.0% in the second quarter. Hantz Financial Services Inc. now owns 181 shares of the company’s stock valued at $25,000 after buying an additional 179 shares during the period. Bessemer Group Inc. increased its position in shares of Krystal Biotech by 106.9% in the third quarter. Bessemer Group Inc. now owns 149 shares of the company’s stock worth $26,000 after acquiring an additional 77 shares in the last quarter. AdvisorNet Financial Inc purchased a new position in shares of Krystal Biotech in the 3rd quarter valued at $30,000. Salomon & Ludwin LLC purchased a new position in shares of Krystal Biotech in the 3rd quarter valued at $33,000. Finally, First Horizon Advisors Inc. lifted its holdings in shares of Krystal Biotech by 212.8% during the 2nd quarter. First Horizon Advisors Inc. now owns 244 shares of the company’s stock valued at $34,000 after acquiring an additional 166 shares in the last quarter. Hedge funds and other institutional investors own 86.29% of the company’s stock.

Krystal Biotech Trading Down 7.3%

The business’s 50-day moving average is $265.16 and its two-hundred day moving average is $208.78. The stock has a market capitalization of $7.68 billion, a PE ratio of 38.35 and a beta of 0.49.

Krystal Biotech Company Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.